It dilutes them less than would be the case if there were no time limit on export, because the WTO decision and CAMR in turn provide opportunities for a generic version of patented products to be made. These are protected products in Canada that will be made and sent to other countries. If there were no time limit on the manufacture of these drugs, there would be more of a concern for companies.
On November 1st, 2010. See this statement in context.